سعر سترونتيومير 2جم/5جم حبيبيات 7 كيس 2022

Strontiomir (Mira International / El Nile, Egypt): strontium ranelate 2 g granules for oral suspension in sachets, a bone-metabolism modulator for osteoporosis; pack of 7 sachets.

• Severe osteoporosis in postmenopausal women and adult men at high fracture risk when other osteoporosis treatments are not possiblePopulation: Postmenopausal women and adult menEuropean Medicines Agency (EMA)

• Most common adverse reactions in trials were nausea and diarrhoea, usually at the start of treatment; myocardial infarction and venous thromboembolism are increased versus placebo.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to the active substance or excipients; current or previous venous thromboembolism; temporary or permanent immobilisation.International label, same formulation · European Medicines Agency (EMA)
• Established, current or past ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease; uncontrolled hypertension.International label, same formulation · European Medicines Agency (EMA)

• Increased risk of myocardial infarction: assess cardiovascular risk before treatment and regularly (every 6-12 months); stop if ischaemic heart, peripheral arterial or cerebrovascular disease develops or hypertension is uncontrolled.International label, same formulation · European Medicines Agency (EMA)
• Increased incidence of venous thromboembolism; stop during immobilisation and when VTE occurs; re-evaluate in patients over 80 at risk of VTE.International label, same formulation · European Medicines Agency (EMA)
• Life-threatening skin reactions (SJS, TEN, DRESS) have been reported; stop treatment if they occur.International label, same formulation · European Medicines Agency (EMA)

• Food, milk/dairy products, calcium-containing medicinesReduce bioavailability by about 60-70%; separate by at least two hours.European Medicines Agency (EMA)
• Oral tetracyclines and quinolone antibioticsComplex formation reduces antibiotic absorption; suspend strontium ranelate during such treatment.European Medicines Agency (EMA)
• Aluminium/magnesium hydroxide antacidsSlightly reduce absorption when taken before or with the dose; preferably take antacids at least two hours after.European Medicines Agency (EMA)

• No data from use in pregnant women; reversible bone effects in offspring of treated rats and rabbits at high doses; if used inadvertently during pregnancy, treatment must be stopped.International label, same formulation · European Medicines Agency (EMA)
• Physico-chemical data suggest excretion in human milk; should not be used during breast-feeding.International label, same formulation · European Medicines Agency (EMA)

• Strontium ranelate: In vitro increases bone formation (osteoblast precursor replication, collagen synthesis) and reduces bone resorption (osteoclast differentiation and activity), rebalancing bone turnover toward formation.